{"disease":{"id":"newly-diagnosed-cd33-positive-acute-myeloid-leukemia-aml","name":"newly diagnosed cd33 positive acute myeloid leukemia aml"},"drugs":{"marketed":[{"drug_id":"gemtuzumab","indication_name":"newly-diagnosed CD33-positive acute myeloid leukemia (AML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"GEMTUZUMAB","company_name":"Wyeth Pharms Inc","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"100","mechanism":"Mylotarg targets and binds to CD33-positive cancer cells, delivering a cytotoxic agent to destroy them."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"mylotarg","guideline_body":"FDA label","recommendation":"MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older.","line_of_therapy":"1L","evidence_grade":"N/A","guideline_year":null}],"source":"Drug Landscape verified database"}